Sorry, you need to enable JavaScript to visit this website.

Healthcare Professional Resources | XARELTO® (rivaroxaban) HCP
  1. Resources
  2. XARELTO® Resources

Healthcare provider and patient resources

XARELTO WITHME OFFERS COST SUPPORT OPTIONS THAT MAY HELP ELIGIBLE PATIENTS WHO ARE CONCERNED ABOUT PAYING FOR XARELTO®

No matter what insurance your patients have, XARELTO withMe can help them learn about options that may lower out-of-pocket prescription costs, including information about:

  • XARELTO withMe Savings Card for commercially insured patients
  • XARELTO withMe Coverage Gap Support for patients who fall into a coverage gap, such as the Medicare Part D coverage gap or commercial high deductibles

And if they become eligible for cost support along the way, we'll stay in touch and let them know.

XARELTO withMe is designed to help eligible patients:

  • Get educational materials and tools to support them along their treatment journey
  • Find options for both commercially and government-insured patients that may help lower out-of-pocket costs for XARELTO®
  • Keep their treatment routine on track with refill notifications

XARELTO WITHME SAVINGS CARD

Eligible patients using commercial or private insurance can save on out-of-pocket costs for XARELTO®. Depending on the health insurance plan, savings may apply toward co-pay, co-insurance, or deductible.

Eligible commercial patients pay as little as $10 per fill for XARELTO®.

There is a limit to savings per fill. Patients may participate without sharing their income information. Your patient's final out-of-pocket cost after the Savings Card is applied will depend on their insurance plan and pharmacy. Not valid for patients using Medicare, Medicaid, or other government-funded programs to pay for their medications. Patients prescribed XARELTO® 10 mg because of a recent non-surgical hospital discharge or because they have recently undergone hip or knee replacement surgery are not eligible. Enrolled patients will receive personalized refill notifications for their XARELTO® prescriptions based on information collected about them and can opt out of refill notifications at any time by calling 888-XARELTO (888-927-3586). Terms expire at the end of each calendar year and may change. See Savings Card Program Requirements.

Enroll your patients at JanssenCarePathPortal.com/express

XARELTO WITHME COVERAGE GAP SUPPORT

XARELTO withMe offers eligible patients cost support to address coverage gaps—with no income requirements.

Are your patients worried about cost? XARELTO withMe is here to help.

Your patients pay $89 per month for XARELTO® with XARELTO withMe Coverage Gap Support.

If your patients fall into a coverage gap, such as the Medicare Part D coverage gap or commercial high deductibles, they could enroll in XARELTO withMe Coverage Gap Support and pay $89 monthly for a 30-day supply or $250 for a 90-day supply, plus sales tax if applicable, for XARELTO®, if they qualify. See Coverage Gap Support Program Requirements.

 

Only patients can sign up at XARELTOwithMe.com or by calling 888-XARELTO (888-927-3586), Monday-Friday, 8:00 AM-8:00 PM ET.

Patient Savings and Financial Assistance:

XARELTO WITHME COVERAGE GAP SUPPORT Help your patients lower out-of-pocket costs during a coverage gap—with XARELTO withMe Coverage Gap Support.

XARELTO WITHME SAVINGS CARD Patients can enroll for a Savings Card at XARELTOwithMe.com.

CAREGIVER ENROLLMENT THROUGH JANSSEN CAREPATH A caregiver can enroll a patient for a XARELTO withMe Savings Card.

JJPAF An independent, nonprofit organization that gives eligible patients free prescription medicines donated by Johnson & Johnson companies.

Welcome Kits:

NVAF PATIENT WELCOME KIT BROCHURE Your patient’s guide to starting treatment for NVAF

DVT/PE PATIENT WELCOME KIT BROCHURE Your patient’s guide to starting treatment for DVT/PE

CAD/PAD PATIENT BROCHURE Your patient’s guide to starting treatment for CAD/PAD

ORS PATIENT WELCOME KIT BROCHURE Your patient’s guide to starting treatment for ORS

The patient support and resources provided by XARELTO withMe are not intended to provide medical advice, replace a treatment plan from the patient's doctor or nurse, provide case management services or serve as a reason to prescribe XARELTO®

 

CAD = coronary artery disease; DVT = deep vein thrombosis; NVAF = nonvalvular atrial fibrillation; ORS = orthopedic (hip or knee) replacement surgery; PAD = peripheral artery disease; PE = pulmonary embolism.

Filter by Indication

NVAF:

ROCKET AF Patel MR et al. Rivaroxaban versus warfarin in nonvalvular trial

END-STAGE RENAL DISEASE (ESRD) Dias C et al. Pharmacokinetics, pharmacodynamics, and safety of single-dose rivaroxaban in chronic hemodialysis

CAD:

COMPASS Eikelboom JW et al. Rivaroxaban with or without aspirin in stable cardiovascular disease

COMPASS (CAD SUBGROUP) Connolly SJ et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomized, double-blind, placebo-controlled trial

COMPASS (RISK STRATIFICATION) Anand SS et al. Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial

COMPASS (DIABETES SUBGROUP) Bhatt DL et al. Role of combination antiplatelet and anticoagulation therapy in diabetes mellitus and cardiovascular disease

PAD:

COMPASS (PAD SUBGROUP) Anand SS et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomized, double-blind, placebo-controlled trial

VOYAGER Bonaca MP et al. Rivaroxaban in peripheral artery disease after revascularization [article and supplementary appendix]

VTE Prophylaxis:

MAGELLAN (SUBGROUP) FOR ACUTELY ILL MEDICAL PATIENTS Spyropoulos AC et al. Improved benefit risk profile of rivaroxaban in a subpopulation of the MAGELLAN study

DVT/PE Initial:

EINSTEIN DVT The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism

EINSTEIN PE The EINSTEIN PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism

POOLED EINSTEIN DVT AND PE Prins MH et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN DVT and EINSTEIN PE randomized studies

EINSTEIN CANCER SUBGROUPS Prins MH et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN DVT and EINSTEIN PE)

DVT/PE Extended:

EINSTEIN CHOICE EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism

DVT/PE Prophylaxis:

RECORD1 Eriksson BI et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty

RECORD2 Kakkar AK et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomized controlled trial

RECORD3 Lassen MR et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty

DOSING OVERVIEW Condition-specific dosing for XARELTO®

REQUEST AN MSL Schedule time with an MSL

REQUEST A REP Schedule time with a Rep

JANSSEN MD® PROFESSIONAL INFORMATION RESOURCE Access to scientific and clinical information and services for Janssen products, including XARELTO®

PIView the full Prescribing Information for XARELTO®

STARTER PACK FOR DVT/PE 30-day Starter Pack after 6 months of initial treatment

XARELTO WITHME COVERAGE GAP SUPPORT Help your patients lower out-of-pocket costs during a coverage gap—with XARELTO withMe Coverage Gap Support

XARELTO WITHME SAVINGS AND SUPPORT XARELTO withMe supports your patients throughout the treatment journey.

JANSSEN CAREPATH SUPPORT FOR EXPRESS ENROLLMENT Enroll your eligible patients in the XARELTO withMe Savings Card.

CARE4TODAY® CONNECT A helpful medication and appointment-tracking and reminder tool designed to empower users to take an active role in their own health care

NVAF PATIENT WELCOME KIT BROCHURE Your patient’s guide to starting treatment for NVAF

DVT/PE PATIENT WELCOME KIT BROCHURE Your patient’s guide to starting treatment for DVT/PE

CAD/PAD PATIENT BROCHURE Your patient's guide to starting treatment for CAD/PAD

ORS PATIENT WELCOME KIT BROCHURE Your patient’s guide to starting treatment for ORS

PATIENT AFFORDABILITY OPTIONSDownload this resource for your patients to discover options that can make XARELTO® more affordable.

JJPAF An independent, nonprofit organization that gives eligible patients free prescription medicines donated by Johnson & Johnson companies.

ROCKET AF Patel MR et al. Rivaroxaban versus warfarin in nonvalvular trial

END-STAGE RENAL DISEASE (ESRD) Dias C et al. Pharmacokinetics, pharmacodynamics, and safety of single-dose rivaroxaban in chronic hemodialysis

COMPASS Eikelboom JW et al. Rivaroxaban with or without aspirin in stable cardiovascular disease

COMPASS (CAD SUBGROUP) Connolly SJ et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomized, double-blind, placebo-controlled trial

COMPASS (RISK STRATIFICATION) Anand SS et al. Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial

COMPASS (DIABETES SUBGROUP) Bhatt DL et al. Role of combination antiplatelet and anticoagulation therapy in diabetes mellitus and cardiovascular disease

COMPASS (PAD SUBGROUP) Anand SS et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomized, double-blind, placebo-controlled trial

VOYAGER Bonaca MP et al. Rivaroxaban in peripheral artery disease after revascularization [article and supplementary appendix]

MAGELLAN (SUBGROUP) FOR ACUTELY ILL MEDICAL PATIENTS Spyropoulos AC et al. Improved benefit risk profile of rivaroxaban in a subpopulation of the MAGELLAN study

EINSTEIN DVT The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism

EINSTEIN PE The EINSTEIN PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism

POOLED EINSTEIN DVT AND PE Prins MH et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN DVT and EINSTEIN PE randomized studies

EINSTEIN CHOICE EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism

EINSTEIN CANCER SUBGROUPS Prins MH et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN DVT and EINSTEIN PE)

RECORD1 Eriksson BI et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty

RECORD2 Kakkar AK et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomized controlled trial

RECORD3 Lassen MR et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty

DOSING OVERVIEW Condition-specific dosing for XARELTO®

REQUEST AN MSL Schedule time with an MSL

REQUEST A REP Schedule time with a Rep

JANSSEN MD® PROFESSIONAL INFORMATION RESOURCE Access to scientific and clinical information and services for Janssen products, including XARELTO®

PIView the full Prescribing Information for XARELTO®

STARTER PACK FORDVT/PE 30-day Starter Pack after 6 months of initial treatment

XARELTO WITHME COVERAGE GAP SUPPORT Help your patients lower out-of-pocket costs during a coverage gap—with XARELTO withMe Coverage Gap Support

XARELTO WITHME SAVINGS AND SUPPORT XARELTO withMe supports your patients throughout the treatment journey.

JANSSEN CAREPATH SUPPORT FOR EXPRESS ENROLLMENT Enroll your eligible patients in the XARELTO withMe Savings Card.

CARE4TODAY® CONNECT A helpful medication and appointment-tracking and reminder tool designed to empower users to take an active role in their own health care

NVAF PATIENT WELCOME KIT BROCHURE Your patient’s guide to starting treatment for NVAF

DVT/PE PATIENT WELCOME KIT BROCHURE Your patient’s guide to starting treatment for DVT/PE

CAD/PAD PATIENT BROCHURE Your patient’s guide to starting treatment for CAD/PAD

ORS PATIENT WELCOME KIT BROCHURE Your patient’s guide to starting treatment for ORS

PATIENT AFFORDABILITY OPTIONSDownload this resource for your patients to discover options that can make XARELTO® more affordable.

JJPAF An independent, nonprofit organization that gives eligible patients free prescription medicines donated by Johnson & Johnson companies.

ROCKET AF Patel MR et al. Rivaroxaban versus warfarin in nonvalvular trial

END-STAGE RENAL DISEASE (ESRD) Dias C et al. Pharmacokinetics, pharmacodynamics, and safety of single-dose rivaroxaban in chronic hemodialysis

COMPASS Eikelboom JW et al. Rivaroxaban with or without aspirin in stable cardiovascular disease

COMPASS (CAD SUBGROUP) Connolly SJ et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomized, double-blind, placebo-controlled trial

COMPASS (RISK STRATIFICATION) Anand SS et al. Rivaroxaban plus aspirin versus aspirin in relation to vascular risk in the COMPASS trial

COMPASS (DIABETES SUBGROUP) Bhatt DL et al. Role of combination antiplatelet and anticoagulation therapy in diabetes mellitus and cardiovascular disease

VOYAGER Anand SS et al . Rivoraxaban and aspirin in peripheral artery disease lower extremity revascularization: impact of concomitant clopidogrel on efficacy and safety

MAGELLAN (SUBGROUP) FOR ACUTELY ILL MEDICAL PATIENTS Spyropoulos AC et al. Improved benefit risk profile of rivaroxaban in a subpopulation of the MAGELLAN study

EINSTEIN DVT The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism

EINSTEIN PE The EINSTEIN PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism

POOLED EINSTEIN DVT AND PE Prins MH et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN DVT and EINSTEIN PE randomized studies

EINSTEIN CANCER SUBGROUPS Prins MH et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE)

EINSTEIN CHOICE EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism

RECORD1 Eriksson BI et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty

RECORD2 Kakkar AK et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomized controlled trial

RECORD3 Lassen MR et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty